Skip to main content
Log in

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

  • Short Report
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Medical-product development has become increasingly challenging and resource-intensive. In 2004, the Food and Drug Administration (FDA) described critical challenges facing medical-product development by establishing the critical path initiative [1]. Priorities identified included the need for improved modeling and simulation tools, further emphasized in FDA’s 2011 Strategic Plan for Regulatory Science [Appendix]. In an effort to support and advance model-informed medical-product development (MIMPD), the Critical Path Institute (C-Path) [www.c-path.org], FDA, and International Society of Pharmacometrics [www.go-isop.org] co-sponsored a workshop in Washington, D.C. on September 26, 2013, to examine integrated approaches to developing and applying model- MIMPD. The workshop brought together an international group of scientists from industry, academia, FDA, and the European Medicines Agency to discuss MIMPD strategies and their applications. A commentary on the proceedings of that workshop is presented here.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products, Accessed online 26 Feb 2013: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm

  2. Kruhlak NL, Benz RD, Zhou H, Colatsky TJ (2012) (Q)SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther 91:529–534

    Article  CAS  PubMed  Google Scholar 

  3. Wang SJ, Hung HM (2013) Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations. Contemp Clin Trials 36:673–681

    Article  PubMed  Google Scholar 

  4. Avalide drug label, updated in 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020758s064lbl.pdf

  5. Food and Drug Administration (2010) Guidance for Industry: qualification process for drug development tools. Accessed online 3 Apr 2013 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf

  6. Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I et al (2014) The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of Angiotensin receptor blockers. Clin Pharmacol Ther 95:208–215

    Article  CAS  PubMed  Google Scholar 

  7. Gumbo T, Dona CS, Meek C, Leff R (2009) Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197–3204

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Pasipanodya J, Gumbo T (2011) An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 55:24–34

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Marino S, Kirschner DE (2004) The human immune response to Mycobacterium tuberculosis in lung and lymph node. J Theor Biol 227:463–486

    Article  CAS  PubMed  Google Scholar 

  10. Marino S, El-Kebir M, Kirschner D (2011) A hybrid multi-compartment model of granuloma formation and T cell priming in tuberculosis. J Theor Biol 280:50–62

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Jacqmin P, McFadyen L, Wade JR (2010) Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. J Pharmacokinet Pharmacodyn 37:157–177

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. METAMODL http://www.metamodl.com/index.php?/page/metamodl.html

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Klaus Romero.

Appendix

Appendix

  1. A1.

    FDA’s plan to advance regulatory science: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM268225.pdf.

  2. A2.

    Further information on the workshop (including slide presentations): http://c-path.org/modeling-and-simulation-for-medical-product-development-and-evaluation-workshop/.

  3. A3.

    FDA-approved irbesartan-hydrochlorothiazide combination label (see Figs. 1a, b, 2a, 2b): http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020758s064lbl.pdf.

  4. A4.

    Coalition against major diseases: http://c-path.org/programs/camd/.

  5. A5.

    Regulatory decision from FDA on the CAMD AD CTS tool: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm180485.htm.

    Regulatory decision from EMA on the CAMD AD CTS tool: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ved=0CCoQFjAA&url=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Fpages%2Fincludes%2Fdocument%2Fopen_document.jsp%3FwebContentId%3DWC500146179&ei=zB7LUvG3GMrA2QXkrIHICw&usg=AFQjCNGDBQWSJJX5DjqHc-CFZaArfDeReg&sig2=G9ZUieb3VLs-I8lvTI279g.

    AlzForum feature on the regulatory decisions for the CAMD AD CTS tool: http://www.alzforum.org/news/research-news/ad-trial-simulation-tool-receives-regulators-blessings.

    Wall Street Journal features on the use of simulations to improve drug development: http://online.wsj.com/news/articles/SB10001424052702303914304579192033377938714. http://online.wsj.com/news/articles/SB10001424052702304361604579290572010514840.

    Further audiovisual materials on modeling and simulation (for clinicians and non-modelers): http://c-path.org/category/videos/.

  6. A6.

    Public Meeting—FDA/NIH/NSF Workshop on Computer Models and Validation for Medical Devices, June 11–12, 2013: http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm346375.htm.

  7. A7.

    Metamodl: http://www.metamodl.com/index.php?/page/metamodl.html.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, K., Sinha, V., Allerheiligen, S. et al. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn 41, 545–552 (2014). https://doi.org/10.1007/s10928-014-9390-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-014-9390-0

Keywords

Navigation